Ovarian cancer in your 40s is uncommon but not rare. According to National Cancer Institute data, about 7.9% of all ovarian cancer cases are diagnosed in women aged 35 to 44, and 15.6% in women aged 45 to 54. The median age at diagnosis is 63, meaning most cases occur well after the 40s, but this decade is when risk begins to climb meaningfully.
How the Numbers Break Down by Age
Ovarian cancer is strongly age-related. Among all new diagnoses tracked between 2019 and 2023, only about 1.5% occurred in women under 20, and 4.9% in women aged 20 to 34. The 35-to-44 bracket accounts for roughly 8% of cases, and the 45-to-54 bracket roughly 16%. That means a woman in her late 40s faces noticeably higher risk than a woman in her early 40s, even though both fall well below the peak incidence seen in the 60s and 70s.
To put it in practical terms: ovarian cancer is the 11th most common cancer in women overall. Your individual risk during any single year in your 40s remains low. But because there is no reliable screening test, even a modest risk level deserves attention, particularly if you have certain genetic factors.
Why Your 40s Are a Turning Point for Risk
The jump from the 35-to-44 bracket (7.9% of cases) to the 45-to-54 bracket (15.6%) reflects a near doubling in the share of diagnoses. This tracks with hormonal changes leading up to menopause. Lifetime ovulation count matters: every ovulatory cycle causes minor damage and repair to the ovarian surface, and decades of that cycle accumulate. Women who have used oral contraceptives for several years, had pregnancies, or breastfed for extended periods tend to have somewhat lower risk because those experiences reduce total lifetime ovulations.
Genetics play an outsized role for women diagnosed younger than the median age. Inherited mutations in the BRCA1 and BRCA2 genes dramatically increase ovarian cancer risk. The National Comprehensive Cancer Network recommends that women who carry a BRCA1 mutation discuss preventive surgery between ages 35 and 40, and BRCA2 carriers between 40 and 45. For women with mutations in other high-risk genes like BRIP1 or RAD51C/D, the recommended window is 45 to 50. If a close family member was diagnosed with ovarian cancer at a young age, the timeline may shift 5 to 10 years earlier than those standard windows.
Types of Ovarian Cancer in This Age Group
Not all ovarian cancers are the same, and the type you’re most likely to encounter depends partly on age. The vast majority of ovarian cancers are surface epithelial tumors, which form in the tissue lining the ovary. In the 40-to-60 age range, about 58.5% of epithelial tumors occur. High-grade serous carcinoma, the most aggressive and most common subtype, peaks in this middle-age window, with roughly 69% of those cases diagnosed between 40 and 60.
Germ cell tumors, which develop from the egg-producing cells, are more common in younger women (under 40) and account for a small fraction of cases in the 40s. Sex cord-stromal tumors, another uncommon type, are spread more evenly across age groups. For a woman in her 40s, the practical takeaway is that epithelial cancers, and specifically the high-grade serous type, are the main concern.
Symptoms That Mimic Perimenopause
One of the biggest challenges for women in their 40s is that ovarian cancer symptoms overlap significantly with perimenopause. Persistent bloating, difficulty eating or feeling full quickly, nausea, and abdominal or pelvic discomfort are hallmarks of ovarian cancer. They’re also things many women in their 40s experience as hormones begin shifting. The American Cancer Society has noted that this overlap means concerning symptoms sometimes get written off as normal midlife changes.
The key distinction is persistence and progression. Perimenopausal bloating tends to come and go with your cycle. Ovarian cancer symptoms are typically present most days and gradually worsen over weeks. If you notice bloating that doesn’t resolve, a noticeable change in how much you can eat, pelvic pressure, or increased urinary frequency that lasts more than two to three weeks, those symptoms warrant investigation rather than reassurance that it’s “just perimenopause.”
Why There’s No Routine Screening
Unlike cervical cancer (which has the Pap smear) or breast cancer (which has mammography), there is no effective screening test for ovarian cancer in the general population. The U.S. Preventive Services Task Force actively recommends against routine screening in women without known high-risk genetic syndromes. This is a Grade D recommendation, their strongest discouragement.
The reason isn’t a lack of available tests. Transvaginal ultrasound and blood tests measuring CA-125 (a protein that can be elevated in ovarian cancer) both exist and are commonly used to evaluate women who already have symptoms. But in large screening trials, these tests produced too many false positives in healthy women, leading to unnecessary surgeries, anxiety, and complications without improving survival rates. The tests are useful for diagnosis but not for catching cancer early in women who feel fine.
Women with a family history of ovarian or breast cancer are a different story. If you have a first-degree relative (mother, sister, daughter) who had ovarian cancer, or multiple relatives with breast cancer, the USPSTF recommends genetic counseling and, if appropriate, genetic testing for BRCA1 and BRCA2 mutations. Knowing your genetic status opens the door to more targeted monitoring or preventive options.
Preventive Surgery for High-Risk Women
For women who carry a confirmed high-risk gene mutation, preventive removal of the ovaries and fallopian tubes is the most effective way to reduce ovarian cancer risk. This procedure reduces the incidence of ovarian cancer by about 94% and overall mortality by about 68%, according to Cochrane review data. Those are striking numbers, and they explain why this surgery is strongly considered for women in the relevant age windows.
The timing recommendations vary by gene. BRCA1 carriers face risk earlier and are counseled about surgery between 35 and 40. BRCA2 carriers can often wait until 40 to 45 because their cancer risk rises somewhat later. For mutations in BRIP1 and RAD51C/D, the recommended window is 45 to 50. Removing the ovaries before natural menopause does bring on surgical menopause, with its own health implications for bone density, heart health, and quality of life. These tradeoffs are real, and the decision involves weighing a large cancer risk reduction against the effects of early hormone loss.
What Younger Diagnosis Means for Outcomes
Women diagnosed with ovarian cancer in their 40s generally have better survival outcomes than those diagnosed in their 60s or 70s, for several reasons. Younger women tend to tolerate treatment better, are more likely to have fewer coexisting health conditions, and are somewhat more likely to have cancer subtypes with better prognoses. Germ cell tumors, for instance, are highly curable even at advanced stages, and they’re more common in younger patients.
However, ovarian cancer at any age is often caught late. Across all age groups, the majority of cases are diagnosed after the cancer has already spread beyond the ovary. There is no age-specific staging data that cleanly separates 40-somethings from older women, but the overall pattern holds: because symptoms are vague and there’s no screening, most ovarian cancers are found at an advanced stage regardless of the patient’s age. This is exactly why paying attention to persistent, unexplained symptoms matters so much in your 40s, when it’s tempting to attribute everything to hormonal change.